RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-7.01%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$880M
AUM Growth
+$880M
(-13%)
Cap. Flow
-$43M
Cap. Flow
% of AUM
-4.88%
Top 10 Holdings %
Top 10 Hldgs %
31.67%
Holding
96
New
7
Increased
27
Reduced
39
Closed
10
Top Buys
| 1 |
Abbott
ABT
|
$8.69M |
| 2 |
Boston Scientific
BSX
|
$8.01M |
| 3 |
Humana
HUM
|
$7.72M |
| 4 |
Thermo Fisher Scientific
TMO
|
$7.25M |
| 5 |
Royalty Pharma
RPRX
|
$6.31M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$16.1M |
| 2 |
Centene
CNC
|
$15.7M |
| 3 |
Eli Lilly
LLY
|
$10.9M |
| 4 |
McKesson
MCK
|
$10.4M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$8.57M |
Sector Composition
| 1 | Healthcare | 98.45% |
| 2 | Industrials | 0.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cigna
CI
$80.3B
| $29.3M | 3.32% | 111,000 -1,000 | -0.9% | -$264K |
|
|
2
Eli Lilly
LLY
$657B
| $29.2M | 3.32% | 90,000 -33,500 | -27% | -$10.9M |
|
3
AbbVie
ABBV
$372B
| $29.1M | 3.31% | 190,000 -5,000 | -3% | -$766K |
|
4
UnitedHealth
UNH
$281B
| $28.8M | 3.27% | 56,000 -2,000 | -3% | -$1.03M |
|
5
Pfizer
PFE
$141B
| $28.3M | 3.22% | 540,000 +17,500 | +3% | +$918K |
|
6
Elevance Health
ELV
$71.8B
| $27.5M | 3.13% | 57,000 +10,801 | +23% | +$5.21M |
|
|
7
Boston Scientific
BSX
$156B
| $27M | 3.07% | 725,000 +215,000 | +42% | +$8.01M |
|
8
CVS Health
CVS
$92.8B
| $26.9M | 3.05% | 290,000 +55,000 | +23% | +$5.1M |
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $26.8M | 3.04% | 95,000 +5,500 | +6% | +$1.55M |
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $25.9M | 2.95% | 325,299 -10,538 | -3% | -$841K |
|
11
Jazz Pharmaceuticals
JAZZ
$7.75B
| $25M | 2.84% | 160,000 -21,976 | -12% | -$3.43M |
|
12
Merck
MRK
$210B
| $24.2M | 2.75% | 265,000 +40,000 | +18% | +$3.65M |
|
|
13
McKesson
MCK
$85.4B
| $20.6M | 2.33% | 63,000 -32,000 | -34% | -$10.4M |
|
|
14
Thermo Fisher Scientific
TMO
$186B
| $20.2M | 2.29% | 37,100 +13,350 | +56% | +$7.25M |
|
|
15
Humana
HUM
$36.5B
| $20.1M | 2.29% | 43,000 +16,500 | +62% | +$7.72M |
|
|
16
Abbott
ABT
$231B
| $18.5M | 2.1% | 170,000 +80,000 | +89% | +$8.69M |
|
|
ABMD
17
DELISTED
Abiomed Inc
ABMD
| $18.1M | 2.05% | 73,000 +5,000 | +7% | +$1.24M |
|
18
Johnson & Johnson
JNJ
$427B
| $17.8M | 2.02% | 100,000 -13,000 | -12% | -$2.31M |
|
19
Cencora
COR
$56.5B
| $17.7M | 2.01% | 125,000 +17,000 | +16% | +$2.41M |
|
20
Intuitive Surgical
ISRG
$170B
| $14.1M | 1.6% | 70,000 +17,500 | +33% | +$3.51M |
|
21
Tenet Healthcare
THC
$16.3B
| $13.7M | 1.56% | 261,000 +58,000 | +29% | +$3.05M |
|
22
Danaher
DHR
$147B
| $13.7M | 1.56% | 54,000 +20,000 | +59% | +$5.07M |
|
|
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
| $13.6M | 1.55% | 240,000 | – | – |
|
|
SWAV
24
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $13.6M | 1.54% | 70,978 +16,178 | +30% | +$3.09M |
|
25
Medtronic
MDT
$119B
| $13.5M | 1.53% | 150,000 -10,000 | -6% | -$898K |
|